左乙拉西坦治疗药物监测的研究进展  

Research progress in therapy drug monitoring of levetiracetam

作　　者：高畅 倪斌 陈芳辉[1] 郭春钰[1] 魏桂林[1] GAO Chang;NI Bin;CHEN Fanghui;GUO Chunyu;WEI Guilin(Dept.of Pharmacy,the First Affiliated Hospital of Gannan Medical University,Jiangxi Ganzhou 341001,China;Ganzhou Key Laboratory of Immunotherapeutic Drugs Developing for Childhood Leukemia,Jiangxi Ganzhou 341000,China)

机构地区：[1]赣南医学院第一附属医院药学部,江西赣州341001 [2]赣州市儿童白血病肿瘤免疫治疗药物研发重点实验室,江西赣州341000

出　　处：《中国药房》2024年第2期251-256,共6页China Pharmacy

基　　金：江西省卫生健康委科技计划项目(No.202130626);赣州市指导性科技计划项目(No.GZ2021ZSF040);赣州市卫生健康委员会市级科研计划项目(No.2020-2-89);赣南医学院第一附属医院博士启动项目(No.QD074)。

摘　　要：左乙拉西坦(LEV)是第二代广谱抗癫痫药物,具有起效快、半衰期短、疗效确切、耐受性好、药物相互作用少等优点。为提高LEV的临床效果,减少不良反应的发生,应对儿童、妊娠期妇女、老年人、肾功能不全等特殊人群予以治疗药物监测(TDM)。临床上LEV监测样本常选择血浆或血清,监测方法多选择免疫分析法或色谱分析法。LEV的有效浓度范围目前尚无统一意见,血药浓度与不良反应的相关性也不明确。影响LEV血药浓度的因素主要有年龄、妊娠及患者用药依从性等。如何解读TDM结果并根据结果调整给药剂量是今后工作的重点。Levetiracetam(LEV)is the second generation of broad-spectrum anti-epileptic drug.LEV has the advantages of rapid absorption,short half-life,precise efficacy,good tolerance and few drug interactions.In order to improve the clinical efficacy of LEV,and reduce the occurrence of adverse reactions,children,pregnant women,the elderly,and patients with renal insufficiency should receive therapeutic drug monitoring(TDM).Clinically,the samples are usually plasma or serum,and the TDM methods are mostly immunoassay or chromatography.There is currently no consensus on the effective concentration range of LEV,and the correlation between plasma concentration and adverse reactions is also unclear.The main factors affecting LEV plasma concentration include age,pregnancy,and patient compliance.How to interpret TDM results and adjust dosage based on the results will be the focus of future work.

关 键 词：左乙拉西坦 治疗药物监测 合理用药 血药浓度 

分 类 号：R971.6[医药卫生—药品] R969[医药卫生—药学]